Randomized Clinical Trial
Copyright ©The Author(s) 2022.
World J Hepatol. Mar 27, 2022; 14(3): 634-646
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.634
Figure 2
Figure 2 Serum ammonia concentration in patients with hepatic encephalopathy receiving treatment with lactulose, rifaximin and probiotics E. coli Nissle 1917 (n = 14 in each group).aP < 0.05 as compared to pre-treatment levels; bP < 0.05 as compared to the lactulose treatment. E. coli: Escherichia coli.